18F-FDG PET/CT Normal Variants, Artefacts and Pitfalls in Thyroid Cancer

  • Arun SasikumarEmail author
  • Alexis Corrigan
  • Muhammad Umar Khan
  • Gopinath Gnanasegaran
Part of the Clinicians’ Guides to Radionuclide Hybrid Imaging book series (CGRHI)


Please provide affiliation details for the following authors: Arun Sasikumar, Alexis Corrigan, Muhammad Umar Khan.


  1. 1.
    Barrington S, Scarsbrook A: Evidence based indications for the use of PET-CT in the UK. Royal College of Physicians, 2013Google Scholar
  2. 2.
    Corrigan AJ, Schleyer PJ, Cook GJ. Pitfalls and artifacts in the use of PET/CT in oncology imaging. Semin Nucl Med. 2015;45:481–99.CrossRefPubMedGoogle Scholar
  3. 3.
    Culverwell AD, Scarsbrook AF, Chowdhury FU. False-positive uptake on 2-[18F]-fluoro-2-deoxy-D-glucose(FDG) positron-emission tomography/computed tomography (PET/CT) in oncological imaging. Clin Radiol. 2011;66:366–82.CrossRefPubMedGoogle Scholar
  4. 4.
    Purohit BS, Ailianou A, Dulguerov N, Becker CD, Ratib O, Becker M. FDG-PET/CT pitfalls in oncological head and neck imaging. Insights Imaging. 2014;5(5):585–602.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Cook GJR, Fogelman I, Maisey MN. Normal physiological and benign pathological variants of 18-FDG PET scanning: potential for error in interpretation. Semin Nucl Med. 1996;26:308–14.CrossRefPubMedGoogle Scholar
  6. 6.
    Delbeke D, Coleman RE, Guiberteau MJ, et al. Procedure guideline for tumour imaging with 18F-FDG PET/CT 1.0. J Nucl Med. 2006;47(5):885–95.PubMedGoogle Scholar
  7. 7.
    Boellaard R, O’Doherty MJ, Weber WA, et al. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging. 2010;37(1):181–200.CrossRefPubMedGoogle Scholar
  8. 8.
    Shreve PD, Anzai Y, Wahl RL. Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants. Radiographics. 1999;19:61–77.CrossRefPubMedGoogle Scholar
  9. 9.
    Metser U, Miller E, Lerman H, et al. Benign non-physiologic lesions with increased 18F-FDG uptake on PET/CT: characterization and incidence. Am J Roentgenol. 2007;189:1203–10.CrossRefGoogle Scholar
  10. 10.
    Are C, Hsu JF, Ghossein RA, Schoder H, Shah JP, Shaha AR. Histological aggressiveness of fluorodeoxyglucose positron-emission timigram (FDG-PET)-detected incidental thyroid carcinomas. Ann Surg Oncol. 2007;14(11):3210–5.CrossRefPubMedGoogle Scholar
  11. 11.
    Soelberg KK, Bonnema SJ, Brix TH, Hegedüs L. Risk of malignancy in thyroid incidentalomas detected by (18)F-fluorodeoxyglucose positron emission tomography: a systematic review. Thyroid. 2012;22(9):918–25.CrossRefPubMedGoogle Scholar
  12. 12.
    Yasuda S, Shohtsu A, Ide M, et al. Chronic thyroiditis: diffuse uptake of FDG at PET. Radiology. 1998;207(3):775–8.CrossRefPubMedGoogle Scholar
  13. 13.
    Liu Y. Orthopaedic surgery-related benign uptake on FDG-PET: case examples and pitfalls. Ann Nucl Med. 2009;23:701–8.CrossRefPubMedGoogle Scholar
  14. 14.
    Nakamoto Y, Tatsumi M, Hammoud D, et al. Normal FDG distribution patterns in the head and neck: PET/CT evaluation. Radiology. 2005;234:879–85.CrossRefPubMedGoogle Scholar
  15. 15.
    Lee SK, Rho BH, Won KS. Parotid incidentaloma identified by combined 18F-fluorodeoxyglucose whole-body positron emission tomography and computed tomography: findings at gray-scale and power Doppler ultrasonography and ultrasound-guided fine-needle aspiration biopsy or core biopsy. Eur Radiol. 2009;19:2268–74.CrossRefPubMedGoogle Scholar
  16. 16.
    Criado E, Sánchez M, Ramírez J, Arguis P, de Caralt TM, Perea RJ, Xaubet A. Pulmonary sarcoidosis: typical and atypical manifestations at high-resolution CT with pathologic correlation. Radiographics. 2010;6:1567–86.CrossRefGoogle Scholar
  17. 17.
    Abouzied M, Crawford E, Nabi H. 18F-FDG imaging: pitfalls and artifacts. J Nucl Med Technol. 2005;33:145–55.PubMedGoogle Scholar
  18. 18.
    Heusner TA, Hahn S, Hamami ME, et al. Incidental head and neck (18)F-FDG uptake on PET/CT without corresponding morphological lesion: early predictor of cancer development? Eur J Nucl Med Mol Imaging. 2009;36:1397–406.CrossRefPubMedGoogle Scholar
  19. 19.
    Hany TF, Gharehpapagh E, Kamel EM, Buck A, Himms-Hagen J, von Schulthess GK. Brown adipose tissue: a factor to consider in symmetrical tracer uptake in the neck and upper chest region. Eur J Nucl Med Mol Imaging. 2002;29(10):1393–8.CrossRefPubMedGoogle Scholar
  20. 20.
    Barrington SF, Maisey MN. Skeletal muscle uptake of Fluorine-18-FDG: Effect of oral diazepam. J Nucl Med. 1996;37:1127–9.PubMedGoogle Scholar
  21. 21.
    Disibio G, French SW. Metastatic patterns of cancer: results from a large autopsy study. Arch Pathol Lab Med. 2008;132(6):931–9.PubMedGoogle Scholar
  22. 22.
    Chang JM, Lee HJ, Goo JM, et al. False positive and false negative FDG-PET scans in various thoracic diseases. Korean J Radiol. 2006;7(1):57–69.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Hany TF, Heuberger J, Schulthess GK. Iatrogenic FDG foci in the lungs: A pitfall of PET image interpretation. Eur Radiol. 2003;13:2122–7.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Arun Sasikumar
    • 1
    Email author
  • Alexis Corrigan
    • 2
  • Muhammad Umar Khan
    • 3
  • Gopinath Gnanasegaran
    • 4
  1. 1.Consultant and Head of the Department, Department of Nuclear MedicineSt Gregorios International Cancer Care CentreParumalaIndia
  2. 2.Consultant in Radionuclide RadiologyMaidstone HospitalMaidstoneUK
  3. 3.Al-Jahra HospitalAl-JahraKuwait
  4. 4.Department of Nuclear MedicineRoyal Free London NHS Foundation TrustLondonUK

Personalised recommendations